Supriya Lifescience Limited IPO (Supriya Lifescience IPO) Detail Issue Price, Date, News, Allotment Status, GMP, Link, Updates

Supriya Lifescience Limited IPO Company Profile: – 

Supriya Lifesciences Limited is the largest exporter of Chlorpheniramine Meleate, Ketamine Hydrochloride and Salbutamol Sulphate from India, they supply their product to India and Global Pharma companies, around 70% of the revenue come from Export Market where they supply to 86 countries around the globe, Europe and America are their largest market. Supriya plant has certification from all the top Pharma Agencies in the world and has a very strong R&D capability and are regularly entering niche products. Company has shown strong financial performance in last three years and this trend is expected to continue due to china plus one policy and government initiative of becoming self-reliant in API space. At the higher price band of ₹274 Company will trade at P/E of 17.81x post issue FY21E which is inline with other API Company, so we are recommending SUBSCRIBE to this IPOSupriya Lifescience Limited founded in 1987 by Dr Satish Waman Wagh is the leading manufacturer and supplier of Active Pharmaceuticals Ingredients (API). Company has niche product offering of 39 APIs mainly focus on analgesic, anaesthetic, vitamins, anti – asthmatic and anti-allergic. They export 50% of Chlorpheniramine Meleate and 70% of Ketamine Hydrochloride from India. Company has been exporting to 86 countries which include North America, Europe, Asia and Latin America. Supriya has one manufacturing facility in Khed District Ratnagiri Maharashtra which has been approved by USFDA, PDMA Japan, NMPA, Canada Health Department and many other health Agencies.  Company has a strong R&D capability and are constantly innovating new products.

---

---

Supriya Lifescience Limited IPO Details –

Issue Details
Objects of the issue	·Funding New capex requirement of the company ·Repayment/Prepayment of current Borrowing of the company. ·General corporate purposes.
Issue Size	Total issue Size -Rs. 700 Cr. Offer for Sale – Rs. 500 Cr. Fresh Issue – Rs. 200 Cr.
Face value	Rs.2.00 Per Equity Share
Issue Price	Rs. 265 – Rs.274
Bid Lot	54 shares
Listing at	BSE, NSE
Issue Opens:	16thDec, 2021 – 20th Dec, 2021
QIB	75% of Net Issue Offer
Retail	10% of Net Issue Offer
NIB	15% of Net Issue Offer

Trade AnyTime AnyWhere With Elite Empower Mobile App

 

Supriya Lifescience Limited IPO Financial Performance:

Supriya Lifescience Limited IPO Positive outlook of the Firm:

• Company is market in Chlorpheniramine Meleate and Ketamine Hydrochloride.

• Company is constantly innovating has very strong R&D team.

• They are exporting to large number of countries so their dependence on one country is less and their site has approval from many agencies.

• Company financial performance has been very strong and has almost tripled their profits in last 3 year, and their Debt/Equity has improved from 2.38x to 0.55x.

Supriya Lifescience Limited IPO Strengths:

• Company is market leader in Chlorpheniramine Meleate and Ketamine Hydrochloride.

• Company is constantly innovating and entering niche products and has very strong R&D capability.

• They are exporting to large number of countries so their dependence on one country is less and their site has approval from many world agencies.

• Financial performance has been very strong and has almost tripled their profits in last 3 year, and their Debt/Equity has improved from 2.38x to 0.55x.

Supriya Lifescience Limited IPO Key Highlights:

• Revenue increased at 17.73% CAGR from FY19 to FY21, EBITDA Margin has improved from 26.19% to 46.23%.

• PAT has grown at CAGR of 77% from ₹ 39.42 crore in FY19 to ₹123.82 crore in FY21.

• In the first half of FY22 company has reported revenue of ₹ 230.06 crore and a Profit of ₹ 65.95 crore and EBITDA Margin of 43.89%.

• In FY21 company has generated cash flow of ₹ 80 crore and free cash flow of ₹ 31.8 crore.

• In FY 2021, Europe contributed 17.40%, Latin America contributed 19.15%, Asia (ex of India) contributed 29.27% and North America contributed 4.76% of the total revenue.

Supriya Lifescience Limited IPO Risk Factors:

• Company generate significant portion of their revenue from few players, so a loss of customer can significantly affect revenue of the company.

• Company operates in highly regulated sector and they have to comply with the safety and manufacturing norms of various agencies, so any lapses in manufacturing standard can put a ban on their plant.

Supriya Lifescience Limited IPO Shareholding Pattern:

Shareholding Pattern	Pre- Issue	Post Issue
Promoters & Promoter Group	99.98%	68.24%
Public	0.02%	31.76%

Supriya Lifescience Limited IPO Financials:

Particulars (in Rs. Cr.)	As at/ for the year ended March 31, 2021	As at/ for the year ended March 31, 2020	As at/ for the year ended March 31, 2019
Net Worth	268.94	149.19	93.79
Total revenue	385.36	311.64	277.84
Net Profit	123.82	73.40	39.42
Net cash inflow/ (outflows)	79.93	116.06	48.67

Supriya Lifescience Limited IPO Outlook:

Supriya Lifesciences Limited is the largest exporter of Chlorpheniramine Meleate, Ketamine Hydrochloride and Salbutamol Sulphate from India, they supply their product to India and Global Pharma companies, around 70% of the revenue come from Export Market where they supply to 86 countries around the globe, Europe and America are their largest market. Supriya plant has certification from all the top Pharma Agencies in the world and has a very strong R&D capability and are regularly entering niche products. Company has shown strong financial performance in last three years and this trend is expected to continue due to china plus one policy and government initiative of becoming self-reliant in API space. At the higher price band of ₹274 Company will trade at P/E of 17.81x post issue FY21E which is inline with other API Company, so we are recommending SUBSCRIBE to this IPO

Lead Manager Details

1)  ICICI Securities Limited

ICICI Securities Limited ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai – 400 025

Telephone: +91 22 6807 7100

Email: supriya.ipo@icicisecurities.com

Investor Grievance e-mail: customercare@icicisecurities.com

Website: www.icicisecurities.com

Contact Person: Sameer Purohit / Akhil Mohod

SEBI Registration No.: INM000011179

2) Axis Capital Limited

Axis Capital Limited 1st floor, Axis House C-2 Wadia International Centre P.B. Marg, Worli, Mumbai 400 025

Telephone: +91 22 4325 2183

Email: sll.ipo@axiscap.in Investor Grievance

e-mail: complaints@axiscap.in Website: www.axiscapital.co.in

Contact Person: Simran Gadh

SEBI Registration No.: INM000012029

3) Link Intime India Private Limited

Link Intime India Private Limited C-101, 247 Park, 1st Floor, L.B.S. Marg, Vikhroli West Mumbai 400 083 Maharashtra. India

Tel: +91 22 4918 6200

E-mail: supriyalife.ipo@linkintime.co.in

Website: www.linkintime.co.in

Contact Person: Shanti Gopalkrishnan

SEBI Registration No.: INR000004058

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitewealth.in. with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitewealth.in.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL

Need An Assistance: